第十届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 1.东北制药集团股份有限公司（以下简称"公司"）第十届监事会第三次会 议于 2025 年 8 月 16 日发出会议通知，于 2025 年 8 月 26 日以通讯表决的方式召 开。 2.会议应参加监事 3 人，实际参加监事 3 人。 证券代码：000597 证券简称：东北制药 公告编号：2025-059 东北制药集团股份有限公司 议案：关于公司 2025 年半年度报告及摘要的议案 具体内容详见巨潮资讯网披露的《东北制药集团股份有限公司 2025 年半年 度报告》及《东北制药集团股份有限公司 2025 年半年度报告摘要》（公告编号： 2025-057）。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 三、备查文件 东北制药集团股份有限公司第十届监事会第三次会议决议。 特此公告。 东北制药集团股份有限公司监事会 2025 年 8 月 27 日 3.本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《东北制药集团股份有限公司章程》 ...

证券代码：000597 证券简称：东北制药 公告编号：2025-058 议案：关于公司 2025 年半年度报告及摘要的议案 具体内容详见巨潮资讯网披露的《东北制药集团股份有限公司 2025 年半年 度报告》及《东北制药集团股份有限公司 2025 年半年度报告摘要》（公告编号： 2025-057）。 东北制药集团股份有限公司 第十届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 1.东北制药集团股份有限公司（以下简称"公司"）第十届董事会第五次会 议于 2025 年 8 月 16 日发出会议通知，于 2025 年 8 月 26 日以通讯表决的方式召 开。 2.会议应参加董事 11 人，实际参加董事 11 人。 3.本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《东北制药集团股份有限公司章程》的规定，会议形成的决议合法 有效。 二、董事会会议审议情况 会议审议并以记名投票表决方式通过以下议案： 表决结果：同意 11 票，反对 0 票，弃权 0 票。 本议案在提交董事会审议前，已通过董 ...

东北制药集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 东北制药集团股份有限公司 2025 年半年度报告 2025 年 8 月 1 东北制药集团股份有限公司 2025 年半年度报告全文 公司负责人周凯、主管会计工作负责人周雅娜及会计机构负责人(会计主 管人员)夏田声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告所涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 投资者及相关人士均应当对此保持足够的风险认识，并应当理解计划、预测 与承诺之间的差异，敬请投资者注意投资风险。 公司未来经营发展受各种风险因素影响，公司已在本报告第三节"管理 层讨论与分析"之"十、公司面临的风险和应对措施"部分就此进行说明， 敬请广大投资者注意。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | . | | | | --- | --- | --- | | | 1 | . 4 ...

Core Points - Northeast Pharmaceutical reported a revenue of 3.853 billion yuan for the first half of 2025, representing a year-on-year decline of 7.58% [1] - The net profit for the same period was 129 million yuan, down 17.62% year-on-year [1] - The company announced plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves [1]

Group 1 - The company Northeast Pharmaceutical (000597) reported that as of August 20, 2025, the number of shareholders is approximately 51,100 [1]

Core Insights - The article highlights the strategic focus of Northeast Pharmaceutical, a subsidiary of Fangda Group, on attracting high-level talent to drive innovation and development in the pharmaceutical industry [2][4]. Group 1: Talent Strategy - Fangda Group emphasizes the importance of recruiting high-end talent to ensure sustainable development over the next 10 to 30 years, aligning talent acquisition with the company's overall development strategy [2]. - Northeast Pharmaceutical plans to recruit 300 master's and doctoral graduates annually for three consecutive years, focusing on drug research and development, chemical drug transformation, cell therapy technology breakthroughs, and modernization of traditional Chinese medicine [2][4]. Group 2: Talent Attraction - The company has established a comprehensive research and development system covering chemical drugs, biological drugs, and traditional Chinese medicine, enhancing its appeal to new talent [3]. - Recruitment efforts included engaging with 28 universities and participating in 35 job fairs, resulting in the selection of 100 master's and doctoral graduates from over 1,600 applications [3]. Group 3: Employee Welfare - Northeast Pharmaceutical offers competitive salaries and unique benefits such as medical expense assistance, mobile phone allowances, and family-oriented programs, fostering a supportive environment for employees and their families [5]. - The company has created a comprehensive talent management system that includes recruitment, training, and retention strategies, ensuring a positive cycle of talent engagement and contribution to the company [5].

Group 1 - The company Northeast Pharmaceutical disclosed that as of July 31, the number of shareholders was 46,700, which represents a decrease of 3,600 shareholders compared to the previous period (July 20), resulting in a month-on-month decline of 7.16% [2]

Group 1 - Northeast Pharmaceutical has experienced a continuous decline for six trading days, with a cumulative drop of -5.55% [1] - The company is a listed subsidiary of Liaoning Fangda Group Industrial Co., Ltd. [1] - Southern Fund's Southern CSI 1000 ETF is among the top ten shareholders of Northeast Pharmaceutical and has reduced its holdings in the first quarter of this year [1] Group 2 - The Southern CSI 1000 ETF has achieved a year-to-date return of 14.26%, ranking 765 out of 2930 in its category [2] - The fund's performance over different periods includes a 0.15% increase over the past week, 6.92% over the past month, and 14.29% over the past three months [2] - The average performance of similar funds is lower, with a year-to-date return of 10.14% [2] Group 3 - The fund manager of Southern CSI 1000 ETF is Ms. Cui Lei, who has a master's degree in financial engineering from Cornell University and holds multiple financial certifications [3][4] - Ms. Cui has extensive experience in fund management, having held various positions within Southern Fund since 2015 [3][4] - The Southern Fund Management Co., Ltd. was established in March 1998 and has several major shareholders, including Huatai Securities Co., Ltd. and Shenzhen Investment Holdings Co., Ltd. [4]

Core Insights - The cell immunotherapy sector saw a 2.42% increase, ranking 6th among concept sectors, with 42 stocks rising, led by Ruizhi Pharmaceutical with a 20% limit-up [1] - Major inflows were observed in the cell immunotherapy sector, with a net outflow of 239 million yuan, while 31 stocks experienced net inflows, with Ruizhi Pharmaceutical leading at 235 million yuan [1][2] Group 1: Sector Performance - The cell immunotherapy concept had a 2.42% increase, with notable performers including Ruizhi Pharmaceutical (20.02%), Sanyuan Gene (20.76%), and Haitai Biological (15.28%) [1] - The sector's performance was contrasted by declines in stocks like Saili Medical (-4.62%), Zexin Pharmaceutical (-3.47%), and Xue Rong Biological (-2.39%) [1] Group 2: Fund Flow Analysis - Ruizhi Pharmaceutical, Jinyu Medical, and Chengda Pharmaceutical had the highest net inflow ratios at 15.31%, 10.34%, and 9.67% respectively [2] - The top stocks by net inflow included Ruizhi Pharmaceutical (234.82 million yuan), Hanyu Pharmaceutical (73.39 million yuan), and Jiu Zhitang (49.52 million yuan) [2][3] Group 3: Stock Performance - Stocks like Haitai Biological and Yuedong Pharmaceutical showed significant gains, with Haitai Biological rising by 15.28% and Yuedong Pharmaceutical by 9.96% [1][4] - Conversely, stocks such as Saili Medical and Zexin Pharmaceutical faced notable declines, with Saili Medical down by 4.62% and Zexin Pharmaceutical by 3.47% [5]

证券代码：000597 证券简称：东北制药 公告编号：2025-056 东北制药集团股份有限公司 关于聘任董事会秘书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 东北制药集团股份有限公司（以下简称"公司"）于2025年7月28日召开第十届 董事会第四次会议，审议通过了《关于聘任董事会秘书的议案》。具体情况如下： 传真：024-25806400 经公司董事长周凯先生提名，公司董事会提名委员会审核，公司董事会同意聘 任宋立志先生为董事会秘书（简历详见附件），任期自本次董事会审议通过之日起 至第十届董事会届满之日止。同时，公司董事长周凯先生不再代行董事会秘书职责。 宋立志先生已取得深圳证券交易所颁发的《董事会秘书资格证书》，熟悉董事 会秘书履职相关的法律法规，具备与岗位相应的专业能力，符合《中华人民共和国 公司法》《深圳证券交易所股票上市规则》等法律法规及《公司章程》的规定。 联系电话：024-25806963 电子邮箱：dshbgs@nepharm.com.cn 联系地址：沈阳经济技术开发区昆明湖街8号 宋立志先生的联系方式如下： 1 附件： 董事会秘书 ...